Ampio Pharmaceuticals, Inc. (AMPE)
USD 0.03
(20.42%)
USD 0.03
(20.42%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -9.51 Million USD | 60.68% |
| 2022 | -24.2 Million USD | 3.78% |
| 2021 | -25.15 Million USD | -65.31% |
| 2020 | -15.21 Million USD | 35.09% |
| 2019 | -23.44 Million USD | -109.64% |
| 2018 | -11.18 Million USD | 28.15% |
| 2017 | -15.56 Million USD | 8.88% |
| 2016 | -17.08 Million USD | 48.71% |
| 2015 | -33.3 Million USD | 14.77% |
| 2014 | -39.07 Million USD | -62.63% |
| 2013 | -24.02 Million USD | -103.23% |
| 2012 | -11.82 Million USD | -6.17% |
| 2011 | -11.13 Million USD | -66.07% |
| 2010 | -6.7 Million USD | -30552.91% |
| 2009 | -21.87 Thousand USD | 25.18% |
| 2008 | -29.23 Thousand USD | -0.79% |
| 2007 | -29 Thousand USD | -2788.65% |
| 2006 | -1004.00 USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 FY | -9.51 Million USD | 60.68% |
| 2023 Q2 | -1.37 Million USD | 67.97% |
| 2023 Q1 | -4.28 Million USD | -39.08% |
| 2023 Q3 | -1.22 Million USD | 10.36% |
| 2023 Q4 | -2.21 Million USD | -80.23% |
| 2022 Q3 | -4.95 Million USD | 37.1% |
| 2022 Q1 | -8.3 Million USD | -33.37% |
| 2022 FY | -24.2 Million USD | 3.78% |
| 2022 Q4 | -3.07 Million USD | 37.86% |
| 2022 Q2 | -7.87 Million USD | 5.14% |
| 2021 Q4 | -6.22 Million USD | -61.62% |
| 2021 Q3 | -3.85 Million USD | -4.85% |
| 2021 Q1 | -3.81 Million USD | 2.35% |
| 2021 Q2 | -3.67 Million USD | 3.82% |
| 2021 FY | -25.15 Million USD | -65.31% |
| 2020 Q2 | -2.6 Million USD | 56.82% |
| 2020 FY | -15.21 Million USD | 35.09% |
| 2020 Q1 | -6.02 Million USD | 15.74% |
| 2020 Q3 | -3.3 Million USD | -27.0% |
| 2020 Q4 | -3.91 Million USD | -18.44% |
| 2019 Q3 | -5.17 Million USD | -44.43% |
| 2019 FY | -23.44 Million USD | -109.64% |
| 2019 Q4 | -7.14 Million USD | -38.15% |
| 2019 Q2 | -3.58 Million USD | -33.83% |
| 2019 Q1 | -2.67 Million USD | -5.48% |
| 2018 Q3 | -1.94 Million USD | 38.01% |
| 2018 Q4 | -2.53 Million USD | -30.77% |
| 2018 FY | -11.18 Million USD | 28.15% |
| 2018 Q1 | -3.56 Million USD | 25.77% |
| 2018 Q2 | -3.12 Million USD | 12.24% |
| 2017 Q2 | -4.69 Million USD | -56.18% |
| 2017 FY | -15.56 Million USD | 8.88% |
| 2017 Q4 | -4.8 Million USD | -56.72% |
| 2017 Q3 | -3.06 Million USD | 34.64% |
| 2017 Q1 | -3 Million USD | -1.86% |
| 2016 FY | -17.08 Million USD | 48.71% |
| 2016 Q4 | -2.94 Million USD | 11.83% |
| 2016 Q2 | -4.36 Million USD | 31.99% |
| 2016 Q1 | -6.42 Million USD | 37.69% |
| 2016 Q3 | -3.34 Million USD | 23.44% |
| 2015 Q4 | -10.3 Million USD | -34.36% |
| 2015 Q2 | -7.72 Million USD | -1.61% |
| 2015 Q1 | -7.59 Million USD | 25.19% |
| 2015 Q3 | -7.67 Million USD | 0.64% |
| 2015 FY | -33.3 Million USD | 14.77% |
| 2014 Q2 | -8.94 Million USD | 14.65% |
| 2014 Q4 | -10.15 Million USD | -6.96% |
| 2014 Q3 | -9.49 Million USD | -6.23% |
| 2014 FY | -39.07 Million USD | -62.63% |
| 2014 Q1 | -10.47 Million USD | -38.98% |
| 2013 FY | -24.02 Million USD | -103.23% |
| 2013 Q2 | -6.45 Million USD | -58.02% |
| 2013 Q3 | -5.94 Million USD | 7.95% |
| 2013 Q4 | -7.53 Million USD | -26.82% |
| 2013 Q1 | -4.08 Million USD | -8.75% |
| 2012 Q4 | -3.75 Million USD | -34.15% |
| 2012 FY | -11.82 Million USD | -6.17% |
| 2012 Q3 | -2.8 Million USD | -23.59% |
| 2012 Q2 | -2.26 Million USD | 24.37% |
| 2012 Q1 | -2.99 Million USD | 34.15% |
| 2011 Q4 | -4.55 Million USD | -64.28% |
| 2011 Q1 | -2.23 Million USD | -35.68% |
| 2011 FY | -11.13 Million USD | -66.07% |
| 2011 Q3 | -2.76 Million USD | -75.68% |
| 2011 Q2 | -1.57 Million USD | 29.53% |
| 2010 Q1 | -1.47 Million USD | -32427.09% |
| 2010 Q2 | -1.14 Million USD | 22.68% |
| 2010 Q3 | -2.43 Million USD | -112.75% |
| 2010 Q4 | -1.64 Million USD | 32.22% |
| 2010 FY | -6.7 Million USD | -30552.91% |
| 2009 FY | -21.87 Thousand USD | 25.18% |
| 2009 Q1 | -9704.00 USD | -131.82% |
| 2009 Q4 | -4547.00 USD | -15.11% |
| 2009 Q3 | -3950.00 USD | -7.6% |
| 2009 Q2 | -3671.00 USD | 62.17% |
| 2008 Q2 | -2697.00 USD | 81.7% |
| 2008 Q3 | -6376.00 USD | -136.41% |
| 2008 Q4 | -4186.00 USD | 34.35% |
| 2008 FY | -29.23 Thousand USD | -0.79% |
| 2008 Q1 | -14.74 Thousand USD | -134.53% |
| 2007 Q4 | -6285.00 USD | 14.2% |
| 2007 Q1 | -300.00 USD | -19.52% |
| 2007 Q2 | -15.09 Thousand USD | -4930.67% |
| 2007 FY | -29 Thousand USD | -2788.65% |
| 2007 Q3 | -7325.00 USD | 51.46% |
| 2006 FY | -1004.00 USD | 0.0% |
| 2006 Q4 | -251.00 USD | 0.0% |
| 2006 Q3 | -251.00 USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| America Great Health | -492.64 Thousand USD | -1832.024% |
| Aridis Pharmaceuticals, Inc. | -29.99 Million USD | 68.266% |
| Biora Therapeutics, Inc. | -67.14 Million USD | 85.824% |
| Bio-Path Holdings, Inc. | -15.84 Million USD | 39.923% |
| Better Therapeutics, Inc. | -38.26 Million USD | 75.124% |
| Calithera Biosciences, Inc. | -42.07 Million USD | 77.378% |
| Comera Life Sciences Holdings, Inc. | -11.97 Million USD | 20.485% |
| Gene Biotherapeutics, Inc. | - USD | Infinity% |
| eFFECTOR Therapeutics, Inc. | -33.84 Million USD | 71.877% |
| Eloxx Pharmaceuticals, Inc. | -34.41 Million USD | 72.347% |
| Evelo Biosciences, Inc. | -108.46 Million USD | 91.225% |
| Evolutionary Genomics, Inc. | -2.01 Million USD | -372.521% |
| Finch Therapeutics Group, Inc. | -34 Million USD | 72.008% |
| Galera Therapeutics, Inc. | -46.95 Million USD | 79.728% |
| Innovation1 Biotech Inc. | -1.36 Million USD | -596.073% |
| Kiromic BioPharma, Inc. | -19.93 Million USD | 52.265% |
| Molecular Templates, Inc. | -10.46 Million USD | 9.058% |
| Navidea Biopharmaceuticals, Inc. | -14.05 Million USD | 32.261% |
| NexImmune, Inc. | -29.19 Million USD | 67.396% |
| Orgenesis Inc. | -53.63 Million USD | 82.254% |
| Panbela Therapeutics, Inc. | -51.29 Million USD | 81.444% |
| Point of Care Nano-Technology, Inc. | -78.01 Thousand USD | -12099.905% |
| PaxMedica, Inc. Common Stock | -16.14 Million USD | 41.048% |
| Scopus BioPharma Inc. | -11.71 Million USD | 18.753% |
| Sorrento Therapeutics, Inc. | -504.31 Million USD | 98.113% |
| Statera Biopharma, Inc. | -98.34 Million USD | 90.322% |
| TRACON Pharmaceuticals, Inc. | -6.89 Million USD | -37.982% |
| Trevena, Inc. | -35.28 Million USD | 73.028% |
| Vaxxinity, Inc. | -58.28 Million USD | 83.67% |
| Vaccinex, Inc. | -22.88 Million USD | 58.409% |
| Vicapsys Life Sciences, Inc. | -1.04 Million USD | -809.093% |
| Viracta Therapeutics, Inc. | -50.69 Million USD | 81.224% |
| ZIVO Bioscience, Inc. | -7.26 Million USD | -31.048% |